Items tagged with Pharma industry

Open letter to Otsuka: continued concerns about delamanid's accessibility (post with simple image)

Leading doctors, advocacy groups and medical organizations remain concerned on several fronts regarding access to delamanid.

AstraZeneca: Response to TB CAB, CRAG, TAG open letter (post with simple image)

AstraZeneca's response to open letter expressing concern for its departure from tuberculosis and urging the company to ensure continued investment in the field.

Punked by pharma: Public funds for private products (post with simple image)

Tax dollars are making it easier for the drug and diagnostics industry to develop and market essential TB products. Is the public getting a fair return on its investment?  

Is AstraZeneca getting ready to exit antibiotics research? (post with simple image)

For the past year, the fate of antibiotics R&D at AstraZenecahas been uncertain. The drug maker, which possesses what is generally regarded as having the strongest antibiotics pipeline in the pharmaceutical industry, indicated that spending on this area would be reduced as part of a larger cutback and strategic refocusing. Ever since, speculation has grown that antibiotics may be abandoned altogether.

Global differences on patents lead WIPO patent law committee to stumble on future work (post with simple image)

Once again, differences over the role of a World Intellectual Property Organization committee last week came in the way of consensus and prevented delegates from agreeing on future work. At the heart of the discontent was the perceived imbalance of the proposed programme of work, which some said disregarded the interests of developing countries. A speaker for the African region gave a striking speech on the Ebola crisis as an example of the failure of the patent system.

2014 Access to Medicine Index – More being done, but progress is uneven (post with simple image)

17 November 2014 | The world’s leading pharmaceutical companies are doing more to improve access to medicine in developing countries, with a raft of new initiatives, scale-ups and innovations over the last two years. However, the industry struggles to perform well in some practices that matter, according to the 2014 Access to Medicine Index, published Monday.

Developing a drug costs $2.6 billion, but not everyone believes this (post with simple image)

The cost to develop a new drug and win FDA marketing approval is now pegged at nearly $2.6 billion, according to a new report from the Tufts Center for the Study of Drug Development. The estimate will likely hearten drug makers that argue rising prices reflect rising costs, but consumer advocates reacted as if someone was trying to sell them a bridge.

Antibiotic resistance: Why aren’t drug companies developing new medicines to stop superbugs? (post with simple image)

Antibiotics are a critical class of drugs that have failed to earn much investment by pharmaceutical companies in recent years. The industry cites their lack of profitability, so the U.S. government is stepping in with incentives and quick regulatory approvals.

Global pharmaceutical industry calls on governments to work with them to beat the rising threat of antimicrobial resistance (post with simple image)

In a joint declaration more than 80 leading international pharmaceutical, generics, diagnostics and biotechnology companies, as well as key industry bodies, call on governments and industry to work in parallel in taking comprehensive action against antimicrobial resistance.

Tackling drug-resistant infections globally: final report and recommendations (post with simple image)

The Review on Antimicrobial Resistance released its final report and recommendations warning that antimicrobial-resistant infections such as drug-resistant tuberculosis could kill 10 million people a year by 2050 without an urgent expansion of resources and funds.

Page 7 of 8 · Total posts: 0

←First 6 7 8 Last→